336PD - Treatment of Recurrent Glioblastoma (GB) after Radiotherapy (RT) and Temozolomide (TMZ): A retrospective analysis of the GLIOCAT study

Date 09 September 2017
Event ESMO 2017 Congress
Session CNS tumours
Topics Central Nervous System Malignancies
Presenter Miguel Gil
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors M. Gil1, J.M. Velarde2, M. Martinez-Garcia3, O. Gallego4, S. del Barco5, E. Pineda6, C. Mesia7, A. Estival8, N. Vilariño3, J. Marruecos5, E. Verger9, J. Craven10, R. Fuentes11, A. Lucas12, M. Macià13, C. Carrato14, N. Vidal15, R. Velasco16, S. Villa17, C. Balana18
  • 1Medical Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, 08907 - Barcelona/ES
  • 2Biostatistics, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 3Medical Oncology Department, Hospital del Mar, Barcelona/ES
  • 4Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 5Medical Oncology Department, ICO-Girona, Girona/ES
  • 6Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 7Medical Oncology Department, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 8Medical Oncology Department, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 9Radiation Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 10Radiation Oncology Department, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 11Radiation Oncology Department, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 12Radiation Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, 08907 - Barcelona/ES
  • 13Radiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, 08907 - Barcelona/ES
  • 14Pathology, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 15Pathology, Hospital Universitari de Bellvitge, 08907 - L'Hospitalet/ES
  • 16Neuro-oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 17Radiation Oncology, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 18Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES

Abstract

Background

There is no standard treatment in recurrent GB and overall survival (OS) ranges from 3 to 9 months (m). The aim of this study was to identify clinical or biological factors that guide the best therapeutic strategy.

Methods

We identified 397 patients (Pts) from GLIOCAT database (432 patients uniformly treated with Stupp’s regimen) who had recurrent GB: 250 Pts received 1 or more active treatment (TT) and 147 Pts didn’t. We analysed clinical and molecular characteristics, treatments received, OS and progression-free survival (PFS).

Results

The median TT lines after recurrence was 1 (0-5). At 1st recurrence surgery was performed in 51 (30 alone), RT in 8 and systemic therapy (ST) in 208 Pts (189 without any local TT): Bevazicumab (BV) ± Irinotecan (IR) 90; clinical trial (CT) 42; TMZ 27; Nitrosoureas (NU) 27]. Pts without any TT were older (p 

Conclusions

Pts who received TT at recurrence offered a better OS in multivariate analysis. Pts undergoing surgery did not present better OS than those who only received ST. MGMT methylation is not a predictor of better OS in recurrence. Pts treated with BV had longer PFS but not OS.

Clinical trial identification

Legal entity responsible for the study

GLIOCAT

Funding

None

Disclosure

M. Gil-Gil: Membership on a Roche advisory board.

\r\n

All other authors have declared no conflicts of interest.

Disclosure

M. Gil-Gil: Membership on a Roche advisory board.

All other authors have declared no conflicts of interest.